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Abstract
Objectives. The aim of this study was to estimate the cost-effectiveness of a model OA consultation for
OA to support self-management compared with usual care.
Methods. An incremental costutility analysis using patient responses to the three-level EuroQoL-5D (EQ-
5D) questionnaire was undertaken from a UK National Health Service perspective alongside a two-arm
cluster-randomized controlled trial. Uncertainty was explored through the use of cost-effectiveness ac-
ceptability curves.
Results. Differences in health outcomes between the model OA consultation and usual care arms were
not statistically significant. On average, visits to the orthopaedic surgeon were lower in the model OA
consultation arm by 0.28 (95% CI: 0.55, 0.06). The costutility analysis indicated that the model OA
consultation was associated with a non-significant incremental cost of £13.11 (95% CI: 81.09 to 54.85)
and an incremental quality adjusted life year (QALY) of 0.003 (95% CI: 0.03 to 0.02), with a 44%
chance of being cost-effective at a threshold of £20 000 per QALY gained. The percentage of participants
who took time off and the associated productivity cost were lower in the model OA consultation arm.
Conclusion. Implementing National Institute for Health and Care Excellence guidelines using a model OA
consultation in primary care does not appear to lead to increased costs, but health outcomes remain very
similar to usual care. Even though the intervention seems to reduce the demand for orthopaedic surgery,
overall it is unlikely to be cost-effective.
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Rheumatology key messages
. Using a model OA consultation in primary care does not lead to increased costs.
. The model OA consultation appears to reduce referrals to orthopaedic surgery.
. The model OA consultation is unlikely to be cost-effective.
Introduction
OA is most prevalent in older people and is known to ad-
versely affect quality of life [13]. Estimates from the
United States of America (USA) suggest that 12.4 million
adults over the age of 65 years are living with this condi-
tion and around 2.9 million people have a disabling form of
OA. A report by the Royal College of General Practitioners
indicates that about 1 million adults consult with symp-
toms of OA in a year and it is one of the main reasons why
1Research Institute for Primary Care and Health Sciences, Arthritis
Research UK Primary Care Centre, Keele University, Keele, 2Health
Economics Unit, University of Birmingham, Birmingham, 3Haywood
Academic Rheumatology Centre, Staffordshire and Stoke-on-Trent
Partnersip Trust, Stoke-on-Trent and 4Keele Clinical Trials Unit, David
Weatherall Building, Keele University, Keele, UK
*Correspondence to: Sue Jowett, Health Economics Unit, Public
Health Building, University of Birmingham, B15 2TT, UK.
E-mail: s.jowett@bham.ac.uk
Submitted 21 September 2017; revised version accepted
30 January 2018
! The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Rheumatology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use,
distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com 1
RHEUMATOLOGY
C
L
IN
IC
A
L
S
C
IE
N
C
E
Downloaded from https://academic.oup.com/rheumatol gy/advance-a t cle-abstract/doi/10.1093/rheum ology/key037/4937699
by Keele University user
on 27 March 2018
people seek medical care [46]. The total healthcare cost
of OA has been estimated at £1 billion in the UK [5].
Therefore OA places a considerable burden on scarce
healthcare resources. The proportion of older people in
the population has been increasing over time [7], and
with this ageing population, it is expected that the preva-
lence of conditions such as OA will rise. A number of pub-
lished guidelines have been developed to aid the
treatment and management of OA [812]. In the UK, for
example, the National Institute for Health and Care
Excellence (NICE) recommend that patients with OA
should be offered core treatments when they first present
in primary care. These include education and access to
information, advice on local muscle strengthening exer-
cise and general aerobic fitness, and if appropriate,
advice on losing weight [12]. However, there is a gap be-
tween the care that is recommended and that which pa-
tients actually receive, and the core aspects of
assessment and management of OA currently delivered
in primary care do not meet the recommendations of
these guidelines [13, 14]. Therefore, measures need to
be put in place to ensure that resources are used opti-
mally. Consequently, there was a need to develop a prac-
tical approach that could potentially support self-
management of OA and also aid the implementation of
the core NICE guidelines for OA. This led to the develop-
ment of a model OA consultation [15] for older patients
presenting with peripheral joint pain, and training for
health care professionals to support its delivery. The
model OA consultation integrated core recommendations
from NICE and consisted of an OA guidebook written by
patients and health professionals for patients, an
enhanced initial consultation with a general practitioner
(GP), and subsequent follow-up with a practice nurse
(up to four consultations) in a dedicated nurse-led OA
clinic. In addition a practice e-template was developed
to record quality measures of care derived from a system-
atic review of quality indicators for OA [15, 16]. The
Management of OsteoArthritis in Consultations
(MOSAICS) trial compared the model OA consultation
with usual care over a 12-month period. This paper re-
ports the economic evaluation alongside the MOSAICS
trial to assess the cost-effectiveness of the model OA
consultation compared with usual care in patients who
consult with OA.
Methods
The economic evaluation was conducted alongside a two-
arm prospective pragmatic cluster randomized controlled
trial in eight general practices in Cheshire, Shropshire and
Staffordshire, UK. The protocol has been previously pub-
lished [15]. The eight practices were randomized to re-
ceive either the model OA consultation or usual care
(control). Additional details of the intervention can be
found in the supplementary data, section on the model
OA consultation and supplementary Fig. S1, available at
Rheumatology online. The trial on which the present study
is based was approved by the North West 1 Research
Ethics Committee, Cheshire (REC reference: 10/H1017/
76) and was monitored by an Independent Trial Steering
Committee and Data Monitoring Committee (Trial registra-
tion number ISRCTN06984617); no additional ethical ap-
proval was required for this study.
The primary outcome measure for the trial was the
12-item Short Form (SF-12) physical component score
[17]. The health economic analysis initially took the form
of a costconsequence analysis where a description of all
the important results relating to costs and consequences
[(clinical outcomes, EuroQoL-5D (EQ-5D), Short Form Six
Dimension (SF-6D), ICEpop CAPability measure for Adults
(ICECAP-A)] were reported. Subsequently, an incremental
costutility analysis using the quality adjusted life year
(QALY) as an outcome measure was undertaken from a
UK National Health Service (NHS) perspective.
Data collection
Resource use and costs
Information on resource use and time off work due to joint
problems was collected from the postal MOSAICS con-
sultation questionnaires completed by participants at 6
and 12 months’ follow-up. NHS costs included primary
and secondary care contacts, investigations, medication
and contacts with other health care professionals such as
physiotherapists and occupational therapists. Questions
on participant’s personal expenditure focused on private
health care use and over-the-counter treatments [15].
In order to value resource use, unit costs were obtained
from standard sources such as the Unit Costs of Health
and Social Care [18], the British National Formulary [19]
and NHS Reference Costs [20] and applied to resource
use data. Due to the lack of nationally representative unit
cost estimates for private health care, this care was
costed as the NHS equivalent. To obtain the cost of the
model OA consultation, information on the resources used
to deliver the intervention was obtained from patient re-
cords collected throughout the trial. To generate the inter-
vention cost, we obtained records collected as part of the
intervention. These records showed that the average
number of times that trial participants actually saw their
nurse from available records was 2.3. We therefore made
the assumption that everyone in the intervention arm who
actually saw the nurse did so at least 2.3 times. GP costs
were not included as part of the intervention since all par-
ticipants, irrespective of trial intervention arm received
usual care. Costs associated with over-the-counter medi-
cation were based on participant responses to the postal
questionnaires. Unit costs of the resource use items are
presented in supplementary Table S1, available at
Rheumatology online, and are in 201213 prices.
Health and quality of life outcomes
All participants completed the three-level version of
the EQ-5D questionnaire [21] at baseline, 3, 6 and
12 months. EQ-5D index scores were generated using
the UK value set [22] to calculate QALYs over the
12-month period, which was used in the base case ana-
lysis. (The QALY is an outcome measure that takes into
account both the quality and quantity of life associated
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with an intervention). Participants also completed the SF-
12 questionnaire [17], which was used to generate SF-6D
scores [23], and the ICECAP-A questionnaire at baseline,
3, 6 and 12 months. The ICECAP-A is a measure of cap-
ability for adults, which aims to capture an individual’s
freedom to function in five key areas of their life: attach-
ment, autonomy, enjoyment, stability and achievement
[24].
Statistical analysis
Descriptive statistics were used to summarize the main
health economic outcomes (EQ-5D, SF-6D and ICECAP-
A). The costutility analysis was focused on determining
the difference in costs and QALYs between the model OA
consultation and usual care arms. To ensure all eligible
participants were included in the study, missing EQ-5D,
SF-6D, ICECAP-A and costs were imputed using multiple
imputation methodology [25]. An imputation model was
fitted and included 25 imputed datasets. Using EQ-5D
scores, QALYs over a 12-month time period were calcu-
lated for each study participant with the area under the
curve method [26]. Imbalances in baseline utility (EQ-5D)
scores between the model OA consultation and usual care
arms were controlled for using a multiple linear regression
approach [27]. Mean costs associated with each trial arm
were estimated, and due to the skewed nature of the
costs, the difference in mean costs and 95% CIs were
calculated using non-parametric bootstrapping [28]. Net
monetary benefit (E    C) was also estimated for
each participant. This is defined as the change in effect-
iveness/QALYs (E) multiplied by the cost-effectiveness
threshold () minus the change in cost (C) [29]. The
threshold value () used for the estimation of net benefits
was £20 000 per QALY.
The base case took the form of a costutility analysis
from a NHS perspective and was conducted using multi-
level linear modelling (as participants are clustered within
GP practices), a method that has been recommended for
the economic evaluation of cluster trials [30]. The depend-
ent variables were net monetary benefits, costs, QALYs
and cost of work absence. Independent variables
included gender and baseline EQ-5D. Model estimates
of the difference in costs, QALYs and net monetary bene-
fits were used to derive an incremental cost per QALY
gained and an incremental net monetary benefit.
Uncertainty was explored through the use of cost-ef-
fectiveness planes and cost-effectiveness acceptability
curves; these plot the probability that the intervention is
cost-effective against willingness to pay threshold values
[31]. All analyses were carried out in Stata 12, Realcom
and Microsoft Excel [3234]. Discounting was not required
as the follow-up period was 12 months.
Sensitivity analysis
The sensitivity analysis had two main foci. The first was to
explore uncertainties in the trial-based data by using
QALYs generated from the SF-6D to obtain cost-effect-
iveness estimates. The second was to explore broader
societal costs through the inclusion of private health
care costs, for example, over-the-counter medication
costs and private health care utilization costs as well as
productivity costs. The human capital approach [35], was
used to estimate productivity costs using data collected
on employment status at every time point and days off
work due to health. The average wage for each respond-
ent was identified using UK Standard Occupational
Classification coding and annual earnings data for each
job type [36].
Results
A total of 525 participants across the eight randomized
practices were recruited to the cluster trial. Of these,
288 participants were in the practices randomized to the
model OA consultation arm and 237 in practices ran-
domized to the usual care arm. The mean (S.D.) age
across all patients was 67.3 years (10.4) and 59.5%
were female. Follow-up rates at 6 and 12 months were
424 (81%) and 384 (73%), respectively, in the intervention
and control arms. A total of 305 (58.1%) participants pro-
vided complete EQ-5D data at all time points.
Resource use
Primary care visits were generally higher in the usual care
arm. Although the differences were not statistically signifi-
cant, participants in the usual care arm had more visits to
both the GP and the nurse. There was no significant dif-
ference in secondary care visits between trial arms with
the exception of visits to the orthopaedic surgeon, which
was significantly higher in the usual care arm.
Approximately 65% of participants in the usual care arm
had prescribed medication as compared with 59% in the
model OA consultation arm (Table 1).
Health outcomes
Mean EQ-5D and SF-6D scores increased at all time
points over the 12-month period in both the intervention
and usual care arms indicating an improvement in health
status over time. Although these scores were higher in the
usual care arm, the differences were not statistically sig-
nificant. When total QALYs were estimated, the usual care
arm was associated with marginally higher overall QALYs
(in respect to both the EQ-5D and SF-6D). Also, the results
for the between-group differences in ICECAP-A showed
similarly that the usual care arm showed slightly higher
average levels of capability across follow-up (Table 2).
EQ-5D scores were generally lower than SF-6D scores
at all times.
Costs
Overall NHS and health care costs were also higher in the
usual care group compared with the model OA consult-
ation arm. However, these differences were not statistic-
ally significant (Table 3). Table 3 also gives a breakdown of
costs for each intervention. Use of primary and secondary
care, including visits to the orthopaedic surgeon, was
greater in the usual care arm leading to higher costs.
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TABLE 2 Health outcomes over 12 months (imputed analysis)
Health outcome
Model OA consultation
(n=288)
Usual care
(n=237)
Difference
(bootstrapped 95% CI)
EQ-5D scores
Baseline 0.573 (0.298) 0.588 (0.272) 0.015 (0.062, 0.039)
Month 3 0.615 (0.280) 0.631 (0.264) 0.016 (0.064, 0.030)
Month 6 0.637 (0.264) 0.638 (0.259) 0.001 (0.044, 0.044)
Month 12 0.651 (0.262) 0.674 (0.224) 0.023 (0.067, 0.018)
QALYs 0.627 (0.244) 0.639 (0.224) 0.012 (0.054, 0.026)
QALYsa 0.632 0.634 0.002 (0.25, 0.020)
QALYsb 0.003 (0.026, 0.197)
SF-6D scores
Baseline 0.678 (0.139) 0.690 (0.148) 0.012 (0.037, 0.013)
Month 3 0.688 (0.141) 0.696 (0.141) 0.008 (0.033, 0.017)
Month 6 0.687 (0.142) 0.707 (0.144) 0.020 (0.044, 0.004)
Month 12 0.693 (0.139) 0.702 (0.138) 0.009 (0.032, 0.015)
QALY 0.688 (0.128) 0.701 (0.129) 0.013 (0.038, 0.010)
QALYa 0.692 0.696 0.004 (0.03, 0.01)
QALYsb 0.012 (0.03, 0.01)
ICECAP-A
Baseline 0.826 (0.166) 0.851 (0.155) 0.025 (0.053, 0.003)
Month 3 0.828 (0.151) 0.853 (0.155) 0.025 (0.053, 0.001)
Month 6 0.821 (0.160) 0.843 (0.158) 0.022 (0.049, 0.005)
Month 12 0.837 (0.153) 0.846 (0.155) 0.009 (0.038, 0.014)
All figures are means (S.D.) unless otherwise indicated. aAdjusted for baseline Utility. bDifference in QALYs between trial arms
adjusted for baseline utility and gender (regression model). EQ-5D: EuroQoL-5D; ICECAP-A: ICEpop CAPability measure for
Adults; QALY: quality adjusted life year; SF-6D: Short Form Six Dimension.
TABLE 1 Resource use over 12-months (complete cases)
Resource use category
Model OA
consultation
(n=199)
Usual care
(n=155)
Difference
(bootstrapped
95% CI)
Primary care visitsa 1.52 (2.46) 1.99 (3.38) 0.48 (1.18, 0.13)
GP at practice 1.32 (2.11) 1.59 (2.62) 0.28 (0.78, 0.24)
GP at home 0.02 (0.12) 0.01 (0.08) 0.01 (0.11, 0.03)
Nurse at practice 0.19 (0.67) 0.39 (1.29) 0.20 (0.48, 0.01)
Nurse at home 0 0.01 (0.08) 0.01 (0.03, 0)
Other healthcare professionals (attached to practice)b 0.21 (0.86) 0.32 (1.15) 0.12 (0.33, 0.11)
Secondary care visitsc 1.11 (2.65) 1.43 (2.91) 0.32 (0.96, 0.27)
Orthopaedic surgeon 0.34 (0.89) 0.58 (1.37) 0.24 (0.52, 0.003)
Podiatrist 0.13 (0.92) 0.12 (0.80) 0.003 (0.17, 0.17)
Physiotherapist 0.61 (2.01) 0.65 (1.93) 0.04 (0.47, 0.36)
Occupational therapist 0.04 (0.21) 0.07 (0.58) 0.04 (0.16, 0.04)
Other secondary care visitsb 0.16 (0.91) 0.10 (0.51) 0.06 (0.07, 0.24)
Private consultantsd 0.39 (1.66) 0.57 (3.07) 0.18 (0.79, 0.29)
Private other health care professionalsb 0.13 (0.85) 0.04 (0.28) 0.09 (0.02, 0.23)
Hospital investigations/treatmentsb,e, n (%) 82 (41.21) 72 (46.45) 10
Prescribed drugsb,e, n (%) 117 (58.79) 101 (65.16) 16
Over-the-counter drugsb,e, n (%) 98 (49.25) 72 (46.45) 26
All figures are means (S.D.) except where indicated. Resource use items presented in this table were solely obtained from self-
report questionnaires. aIncludes contacts with GP and nurse at home and practice. bPatient-specific. cIncludes contacts with
physiotherapists, occupational therapists podiatrists and orthopaedic surgeons. dIncludes contacts with private physiother-
apists, occupational therapists private podiatrists and private orthopaedic surgeons. eFigures are the number of patients (per
cent) who stated that they had an investigation or a drug. GP: general practitioner.
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Cost-effectiveness
Estimates from the regression model show that the inter-
vention was associated with a lower cost (P= 0.705) and
fewer QALYs (P= 0.786) (Table 4). At a willingness to pay
threshold of £20 000 per QALY, the model OA consult-
ation was associated with a 44% chance of being cost-
effective (Fig. 1).
Sensitivity analysis
When broader health care costs were used, the interven-
tion was still less costly (P= 0.768) and less effective
(P= 0.786) than the usual care arm (Table 5). Costutility
analysis with QALYs generated from the SF-6D yielded
similar results to the base case analysis, that is, the inter-
vention was less costly (P= 0.705) and less effective
(P= 0.187) than the usual care (Table 5). A total of 136
participants were in full-time employment at baseline. Of
these, 40 participants, 20 in each trial arm, took time off
over the 12-month period. Those in the intervention arm
had fewer mean days off work than those in the usual care
arm (P= 0.364). The associated productivity-related cost
was lower in the intervention arm, but the difference was
not statistically significant (Table 5).
Discussion
Summary of main findings
This study sought to assess the cost-effectiveness of the
model OA consultation for the implementation of NICE
guidelines and support for self-management of OA in pri-
mary care. Our results reveal that there was a general
increase in health status across the whole population as
measured by the EQ-5D and SF-6D over the 12-month
period, and although scores were slightly higher in the
usual care arm, the difference was not statistically signifi-
cant. SF-6D scores were higher than EQ-5D scores, a
result which was in line with a previous study [37]. With
the exception of visits to the orthopaedic surgeon, which
was higher in the usual care group, there were no signifi-
cant differences in all other secondary care resource use
items between the trial arms. Participants in the usual care
arm also reported more time off work compared with the
intervention arm. The finding that the intervention may
lead to reduced referrals and less time off work suggests
a possible avenue for future research to identify individual
patients who might benefit from the approach.
The model OA consultation was less expensive than
usual care and although this was not statistically signifi-
cant, one might argue that the exclusion of the cost of
training resulted in this lower cost. However, it should
be noted that there are difficulties associated with the
estimation of a per patient training cost within economic
evaluation studies and also training received would be
used for a large number of patients over a number of
years, resulting in a low mean cost per patient.
The costutility analysis showed that the model OA con-
sultation was less costly but less effective than usual care.
Even though these differences are not statistically
TABLE 3 Per patient costs over 12 months (in pounds)
Resource use category Model OA consultation Usual care
Difference
(bootstrapped 95% CI)
(n= 199), £ (n= 155), £
Primary care visitsa 56.01 (83.53) 69.02 (103.31) 13.01 (35.24, 5.28)
GP at practice 44.76 (71.80) 54.18 (89.01) 9.42 (29.03, 7.41)
GP at home 0.81 (6.55) 0.35 (4.31) 0.46 (0.71, 1.55)
Nurse at practice 2.11 (7.46) 4.61 (15.07) 2.49 (5.50, 0.03)
Nurse at home 0 0.15 (1.87) (0.54, 0)
Other primary care visitsb 8.33 (24.20) 9.74 (29.72) 1.41 (7.37, 3.97)
Secondary care visitsc 60.68 (130.42) 76.48 (156.38) 15.80 (51.40, 14.01)
Orthopaedic surgeon 27.09 (71.66) 44.31 (106.94) 17.22 (37.95, 1.18)
Podiatrist 5.32 (35.65) 4.34 (26.23) 0.98 (5.03, 7.93)
Physiotherapist 21.55 (77.01) 21.74 (70.72) 0.18 (15.47, 16.50)
Occupational therapist 2.06 (11.98) 2.24 (16.93) 0.18 (3.50, 2.61)
Other secondary care visitsb 4.67 (17.85) 3.85 (22.67) 0.81 (4.45, 4.65)
Hospital investigations/treatmentsb 109.71 (401.16) 92.36 (222.66) 17.35 (42.40, 83.75)
Prescribed drugsb 15.51 (20.34) 15.65 (21.47) 0.14 (4.58, 3.86)
Trial intervention cost 11.47 (20.69) 0 11.47 (8.69, 14.42)
Over-the-counter drugsb 27.14 (255.67) 27.93 (121.01) 0.79 (31.51, 50.14)
Private health professionalsb 21.62 (76.54) 29.53 (135.05) 7.91 (39.24, 12.24)
Imputed analysis (n = 288) (n = 237)
Total NHS costsd 227.17 (411.84) 236.11 (345.35) 8.94 (71.79, 57.70)
Total Healthcare costsd 278.56 (535.43) 285.99 (400.43) 7.43 (76.41, 76.26)
All figures are means (S.D.) unless otherwise indicated. aIncludes contacts with GP and nurse at home and practice. bPatient-
specific. cIncludes contacts with physiotherapists, occupational therapists, etc. dUnadjusted costs. GP: general practitioner.
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FIG. 1 Cost-effectiveness plane (model consultation vs control) (A) and CEAC (model consultation vs control) (B)
WTP: willingness to pay.
TABLE 5 Sensitivity analysis
Sensitivity analysis scenario
and outcomes
Difference in mean
(intervention  control)a P-value CI Interpretation
Costutility analysis with SF-6D
NHS costsb, £ 13.11 0.705 81.09, 54.85 Intervention less costly
and less effectiveQALYs (SF-6D)b 0.012 0.187 0.03 , 0.01
Net monetary benefitsb, £ 178.39 0.362 561.74 , 204.96
Costutility analysis with health care costs
Health care costsb, £ 14.14 0.768 108.08, 79.80 Intervention less costly
and less effectiveQALYsb 0.003 0.786 0.03, 0.02
Net monetary benefitsb, £ 34.95 0.883 501.82, 431.92
Time off work and productivity costs
Number of days off over 12 monthsb 1.05 0.364 3.35, 1.23
Mean cost of work absenceb, £ 23.25 0.845 256.32, 209.83
aDifference in mean per patient costs net benefits, QALYs and time off work between trial arms. bAdjusted for baseline utility,
and gender (regression model). NHS: National Health Service; QALY: quality adjusted life year.
TABLE 4 Base case costutility analysis (imputed analysis)
Outcome
Difference in mean
(intervention
 control)a P-value CI Interpretation
NHS costsb, £ 13.11 0.705 81.09, 54.85 Intervention less costly
and less effective.QALYsb 0.003 0.786 0.03 , 0.02
Net monetary benefitsb, £ 33.63 0.887 497.56, 430.30
aDifference in mean per patient cost and QALYs between trial arms. bAdjusted for baseline utility and gender. NHS: National
Health Service; QALY: quality adjusted life year.
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significant, the established approach that is used in health
economics is to conduct a cost-effectiveness analysis,
focusing on the joint estimation of costs and outcomes
[38]. At a cost-effectiveness threshold of £20 000 per
QALY, the probability of the model OA consultation
being cost-effective was low at 44%.
Strengths and weaknesses of the study
A major strength of this study is that it is the first to con-
sider the cost-effectiveness of the model OA consultation
for the implementation of NICE guidelines and support for
self-management of OA in primary care. Second, the
study considered cost-effectiveness in a population con-
sulting with peripheral joint pain and OA in primary care.
Much of the cost-effectiveness studies for OA are based
on studies of knee OA and, as such, our study considered
a population where evidence of cost-effectiveness is lack-
ing. Third, this study considered multiple outcomes and
also considered outcomes broader than just health-
related quality of life, which distinguishes it from other
health economic evaluations, which consider a single out-
come measure. This study also has some limitations. First
is the fact that the main outcome for the health economic
analysis was the three-level EQ-5D, which may not be
sensitive to changes in this disease area [39]. The five-
level version of the EQ-5D [40] is now available and this
is likely to be more sensitive to change. Second, the dif-
ficulty associated with the estimation of a per-patient
training cost led to the exclusion of this cost from the
analysis.
Meaning of the study
Implementing NICE guidelines using a model OA consult-
ation in primary care may not lead to increased costs.
Although the intervention may support some people with
OA to remain in work and reduce the demand for ortho-
paedic surgery, overall it is unlikely to be cost-effective.
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